AN2 Therapeutics, Inc.
AN2 Therapeutics is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics based on their boron chemistry platform. They have a pipeline of boron-based compounds in development for Chagas disease, melioidosis, and NTM lung disease caused by M. abscessus, along with programs focused on targets in oncology and infectious diseases. AN2 is committed to delivering high-impact drugs to patients with critical unmet needs and improving health outcomes.
Registre Officiel
Analyse Qualité IA
Détails du Score de Confiance
Liens Rapides
Points forts du site
🌟 Entreprises similaires de confiance
OKYO Pharma Ltd
OKYO Pharma Ltd. (NASDAQ:OKYO) is a biopharmaceutical company dedicated to developing an innovative treatment for neuropathic corneal pain and dry eye disease. Through its proprietary chemerin peptide, OK-101, the company aims to provide targeted therapy that alleviates pain, controls inflammation, and enhances ocular residence time for more effective, lasting relief.
Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing new treatments for gastrointestinal (GI) diseases, particularly acid-related disorders. They have licensed exclusive rights in the United States, Europe, and Canada to a potassium-competitive acid blocker (PCAB). Phathom is committed to transforming the treatment landscape and improving the lives of patients.
UroGen Pharma Ltd.
UroGen Pharma is a biopharmaceutical company focused on developing and commercializing innovative treatments for urologic cancers. They utilize RTGel® technology for sustained local delivery of medications to the urinary tract. Their key products include Jelmyto® and Zusduri™, representing advancements in uro-oncology treatment.